Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain

Collapse authors list.
Iyer, D, Vartak, SV, Mishra, A, Goldsmith, G, Kumar, S, Srivastava, M, Hegde, M, Gopalakrishnan, V, Glenn, M, Velusamy, M et al (show 5 more authors) , Choudhary, B, Kalakonda, N, Karki, SS, Surolia, A and Raghavan, SC (2016) Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. FEBS JOURNAL, 283 (18). 3408 - 3437. ISSN 1742-464X

Text Iyer_et_al-2016-The_FEBS_Journal.pdf - Author Accepted Manuscript Download (1MB)

Item Type:	Article
Uncontrolled Keywords:	apoptosis, cancer therapeutics, cell death, chemotherapy, genomic instability, leukemia, molecular docking, small molecule inhibitor
Depositing User:	Symplectic Admin
Date Deposited:	06 Apr 2017 15:01
Last Modified:	19 Jan 2023 07:07
DOI:	10.1111/febs.13815
Related URLs:	http://gateway.webofknowledge.com/gatewa...
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3006821

Available Versions of this Item

• Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. (deposited 06 Apr 2017 15:01) [Currently Displayed]
  • Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. (deposited 16 May 2017 10:29)